Can a new drug tame sickle cell pain in kids?
NCT ID NCT02961218
First seen Jan 14, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study tested a drug called canakinumab (ACZ885) in 49 children and young adults (ages 8-20) with sickle cell anemia to see if it could reduce their daily pain. Participants rated their pain on a scale of 0 to 10, and researchers compared changes over 12 weeks between those who got the drug and those who got a placebo. The goal was to find a safer, more tolerable way to manage sickle cell pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Atlanta, Georgia, 30329, United States
-
Novartis Investigative Site
Augusta, Georgia, 30912, United States
-
Novartis Investigative Site
Greenville, North Carolina, 27834, United States
-
Novartis Investigative Site
Toronto, Ontario, M5G 1X8, Canada
-
Novartis Investigative Site
Hamburg, 20246, Germany
-
Novartis Investigative Site
Afula, 1834111, Israel
-
Novartis Investigative Site
Johannesburg, Guateng, 2193, South Africa
-
Novartis Investigative Site
Adana, 01330, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, 06100, Turkey (Türkiye)
-
Novartis Investigative Site
Mersin, 33343, Turkey (Türkiye)
-
Novartis Investigative Site
Wolverhampton, Staffordshire, WS11 5XY, United Kingdom
-
Novartis Investigative Site
London, E1 1BB, United Kingdom
-
Novartis Investigative Site
London, NW1 2BU, United Kingdom
-
Novartis Investigative Site
London, SE1 7EH, United Kingdom
-
Novartis Investigative Site
London, SE5 9RS, United Kingdom
Conditions
Explore the condition pages connected to this study.